EE+ POEM Archive
Oral semaglutide may reduce cardiovascular mortality in patients with T2DM and CV or renal disease (NNT = 100 for 16 months)
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Oral Semaglutide May Reduce Cardiovascular Mortality in Patients With T2DM and CV or Renal Disease (NNT = 100 for 16 Months)." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314909/all/Oral_semaglutide_may_reduce_cardiovascular_mortality_in_patients_with_T2DM_and_CV_or_renal_disease__NNT_=_100_for_16_months_.
Oral semaglutide may reduce cardiovascular mortality in patients with T2DM and CV or renal disease (NNT = 100 for 16 months). In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314909/all/Oral_semaglutide_may_reduce_cardiovascular_mortality_in_patients_with_T2DM_and_CV_or_renal_disease__NNT_=_100_for_16_months_. Accessed October 9, 2024.
Oral semaglutide may reduce cardiovascular mortality in patients with T2DM and CV or renal disease (NNT = 100 for 16 months). (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314909/all/Oral_semaglutide_may_reduce_cardiovascular_mortality_in_patients_with_T2DM_and_CV_or_renal_disease__NNT_=_100_for_16_months_
Oral Semaglutide May Reduce Cardiovascular Mortality in Patients With T2DM and CV or Renal Disease (NNT = 100 for 16 Months) [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2024 October 09]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314909/all/Oral_semaglutide_may_reduce_cardiovascular_mortality_in_patients_with_T2DM_and_CV_or_renal_disease__NNT_=_100_for_16_months_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Oral semaglutide may reduce cardiovascular mortality in patients with T2DM and CV or renal disease (NNT = 100 for 16 months)
ID - 1314909
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314909/all/Oral_semaglutide_may_reduce_cardiovascular_mortality_in_patients_with_T2DM_and_CV_or_renal_disease__NNT_=_100_for_16_months_
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
